Data Knights is a blank check company incorporated as a Delaware corporation on February 8, 2021, for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. Data Knights’ units, common stock and warrants are trading on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbols “DKDCU,” “DKDCA” and “DKDCW,” respectively.

Data Knights LLC (the “Sponsor”) and Data Knights’ officers and directors (together with the Sponsor, the “Insiders”) each have agreed to (i) vote all of their shares of Data Knights Class B Common Stock in favor of the Business Combination and certain other matters, and (ii) certain restrictions on their shares of Data Knights Class B common stock (other than any shares of Data Knights Class B Common Stock received in exchange for Private Placement Warrants (as defined below)), and to take other customary actions to cause the Business Combination to occur. The foregoing description of the Sponsor Support Agreement entered into in connection with the transaction is subject to and qualified in its entirety by reference to the full text of the Sponsor Support Agreement, a copy of which is included as Exhibit 2.3 to Data Knights’ Form 8-K filed with the SEC on April 25, 2022.

At the Closing of the Business Combination, Data Knights’ units will separate into their component shares of Class A common stock and public warrants, and the units will no longer trade separately under “DKDCU.” Data Knights has applied for the listing of the Class A common stock and public warrants on Nasdaq following the Closing of the Business Combination under the symbols “ONMD” and “ONMDU,” respectively. Based on the capitalization of OneMedNet, as of December 31, 2021, the total number of shares of Data Knights Common Stock expected to be issued in connection with the Business Combination is approximately 20,000,000, and holders of equity interests in OneMedNet as of immediately prior to the closing of the Business Combination are expected to hold, in the aggregate, approximately 57% of the issued and outstanding shares of Data Knights Common Stock immediately following the closing of the Business Combination assuming no redemptions by Data Knights stockholders.

OneMedNet is the leading curator of regulatory-grade Imaging Real Word Data (“RWD”), a growing emerging market. Its innovation solutions connect healthcare providers and patients by offering direct access to clinical images and associated contextual patient record. OneMedNet has proven the commercial and regulatory viability of imaging RWD by providing regulatory-grade image-centric RWD that exactly matches OneMedNet’s Life Science Partners’ Case Selection Protocol. With a federated network of over 90 healthcare providers, OneMedNet has the immediate ability to quickly search and extensively curate multi-layer data from a Federated group of healthcare facilities.

As described in the accompanying proxy statement/prospectus, certain officers, directors and equityholders of OneMedNet are parties to the Voting Agreement with Data Knights whereby such parties, among other things, have agreed to vote all of their interests in OneMedNet to approve the Merger Agreement and the Business Combination. As also described in the accompanying proxy statement/prospectus, the Sponsor is a party to the Sponsor Support Agreement with Data Knights and OneMedNet whereby the Sponsor, among other things, has agreed to vote all of its shares of Data Knights Common Stock in favor of approving the proposals described in the accompanying proxy statement/prospectus.

Pursuant to the Charter, Data Knights’ public stockholders have redemption rights in connection with the Business Combination. Data Knights’ public stockholders are not required to affirmatively vote for or against the Business Combination in order to redeem their shares of Class A Common Stock for cash. This means that public stockholders who hold shares of Data Knights Class A Common Stock on or before [·], 2022 (two (2) business days before the Special Meeting) will be eligible to elect to have their shares of Class A common stock redeemed for cash in connection with the Special Meeting, whether or not they are holders as of the Record Date and whether or not such shares are voted at the Special Meeting.

Data Knights is providing this proxy statement/prospectus and accompanying proxy card to Data Knights’ stockholders in connection with the solicitation of proxies to be voted at the Special Meeting and at any adjournments or postponements of the Special Meeting. Whether or not you plan to attend the Special Meeting, Data Knights urges you to carefully read this proxy statement/prospectus (and any documents incorporated into this proxy statement/prospectus by reference). Please pay particular attention to the section titled “Risk Factors” beginning on page 50 of the accompanying proxy statement/prospectus.

To participate in the virtual meeting, a Data Knights stockholder of record will need the 16-digit control number included on your proxy card or instructions that accompanied your proxy materials, if applicable, or to obtain a proxy form from your broker, bank or other nominee. The Data Knights Special Meeting webcast will begin promptly at [●] a.m., Eastern Time.

We strongly encourage Data Knights’ stockholders to access the Data Knights Special Meeting prior to the start time. If you encounter any difficulties accessing the virtual meeting or during the meeting time, please call the technical support number that will be posted on the virtual meeting login page.

Your vote is very important. If you are a registered stockholder of Data Knights, please vote your shares as soon as possible to ensure that your vote is counted, regardless of whether you expect to attend the Special Meeting, by completing, signing, dating, and returning the enclosed proxy card in the postage-paid envelope provided. If you hold your shares in “street name” through a bank, broker, or other nominee, you will need to follow the instructions provided to you by your bank, broker, or other nominee to ensure that your shares are represented and voted at the Special Meeting. The transactions contemplated by the Merger Agreement are conditioned on the approval of the Business Combination and satisfaction of certain other closing conditions described in the accompanying proxy statement.

On behalf of Data Knights’ Board, I would like to thank you for your support and look forward to the successful completion of the Business Combination.

​

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under the accompanying proxy statement or determined that the accompanying proxy statement is accurate or complete. Any representation to the contrary is a criminal offense.

The accompanying proxy statement is dated [●], 2022 and is first being mailed to the stockholders of Data Knights on or about [●], 2022.

​

​

Data Knights Acquisition Corp.

Unit G6, Frome Business Park, Manor Road

Frome

United Kingdom, BA11 4FN

011-44 203 833 4000

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS OF

DATA KNIGHTS ACQUISITION CORP. IN LIEU OF ITS 2022 ANNUAL MEETING

TO BE HELD ON [·], 2022

To the Stockholders of Data Knights Acquisition Corp.:

NOTICE IS HEREBY GIVEN that a special meeting of stockholders (the “Special Meeting”) of Data Knights Acquisition Corp. (“Data Knights”), a Delaware corporation, will be held at [·] a.m. Eastern Time, on [·], 2022. The Special Meeting will be a completely virtual meeting of stockholders, which will be conducted via live webcast. You will be able to attend the Special Meeting online, vote and submit your questions during the Special Meeting by visiting https://www.cstproxy.com/Data Knightscapitalcorp/2022.

At the Special Meeting, Data Knights stockholders will be asked to consider and vote upon the following proposals (each, a “Proposal” and collectively, the “Proposals”), as more fully described in the accompanying proxy statement:

Data Knights’ board of directors (the “Board”) has adopted and approved the Merger Agreement and recommends a vote “FOR” the Business Combination Proposal, “FOR” the Nasdaq Proposal, “FOR” the Charter Amendment Proposal, “FOR” the Election of Directors Proposal, “FOR” the Incentive Plan Proposal and “FOR” the Adjournment Proposal. Data Knights does not expect a vote to be taken on any other matters at the Special Meeting or any adjournment or postponement thereof.

Holders of record of Data Knights’ Class A Common Stock, par value $0.0001 per share, and Data Knights’ Class B Common Stock, par value $0.0001 per share (”Founder Shares,” and collectively with Data Knights’ Class A Common Stock, the “Data Knights Common Stock”) at the close of business on [•], 2022 (the “Record Date”) will be entitled to notice of and to vote at the Special Meeting or any adjournment or postponement thereof. Each share of Data Knights Common Stock entitles the holder thereof to one vote. A complete list of Data Knights stockholders of record entitled to vote at the Data Knights Special Meeting will be available for 10 days before the Data Knights Special Meeting at the principal executive offices of Data Knights for inspection by stockholders by appointment only during ordinary business hours for any purpose germane to the Data Knights Special Meeting. The eligible Data Knights stockholder list will also be available on the Data Knights Special Meeting website for examination by any stockholder attending the Data Knights Special Meeting webcast.

Your attention is directed to the proxy statement/prospectus accompanying this notice (including the financial statements and annexes attached thereto) for a more complete description of the proposed Business Combination and related transactions and each of our Proposals. We encourage you to read the accompanying proxy statement/prospectus carefully. If you have any questions or need assistance voting your shares, please call our proxy solicitor, Laurel Hill Advisory Group LLC at (917) 886-3351 or email Donna M. Ackerly at dackerly@laurelhill.com.

All Data Knights stockholders are cordially invited to attend the Stockholders Meeting in virtual format. Data Knights stockholders may attend, vote and examine the list of Data Knights stockholders entitled to vote at the Stockholders Meeting by visiting https://www.cstproxy.com/Data Knightscapitalcorp/2022 and using the conference ID number 6194641#. To ensure your representation at the Stockholders Meeting, you are urged to complete, sign, date and return the enclosed proxy card as soon as possible. To vote online, please have your proxy card available and visit www.cstproxyvote.com and follow the prompts to vote your shares. If your shares are held in an account at a brokerage firm or bank, you must instruct your broker or bank on how to vote your shares.

Your vote is very important regardless of the number of shares you own. Whether you plan to attend the Stockholders Meeting or not, please sign, date, and return the enclosed proxy card as soon as possible in the envelope provided. If your shares are held in “street name” or are in a margin or similar account, you should contact your broker to ensure that votes related to the shares you beneficially own are properly counted. If you sold or transferred your shares after the record date, it is still important that you vote. Each of the Business Combination Proposal, the Charter Amendment Proposal, the Nasdaq Proposal, the Incentive Plan Proposal, and the Election of Directors Proposal is interdependent upon the others and must be approved in order for Data Knights to complete the Business Combination as contemplated by the Merger Agreement. Other than the Election of Directors Proposal, each of the Proposals require the affirmative vote of a majority of the issued and outstanding shares of Data Knights Common Stock cast by the stockholders represented in person (which would include presence at a virtual meeting) or by proxy at the Stockholders Meeting and entitled to vote thereon, voting as a single class.

​

​

​

​

​

TABLE OF CONTENTS

​

​

​

​

MARKET AND INDUSTRY DATA

Information contained in this prospectus concerning the market and the industry in which OneMedNet competes, including its market position, general expectations of market opportunity and market size, is based on information from various third-party sources, on assumptions made by OneMedNet based on such sources and OneMedNet’s knowledge of the markets for its services and solutions. Any estimates provided herein involve numerous assumptions and limitations, and you are cautioned not to give undue weight to such information. Third-party sources generally state that the information contained in such source has been obtained from sources believed to be reliable but that there can be no assurance as to the accuracy or completeness of such information. The industry in which OneMedNet operates is subject to a high degree of uncertainty and risk. As a result, the estimates and market and industry information provided in this proxy statement/prospectus are subject to change based on various factors, including those described in the section entitled “Risk Factors — Risks Related to OneMedNet’s Business” and elsewhere in this proxy statement/prospectus.

​

​

SUMMARY TERM SHEET

This Summary Term Sheet, together with the sections titled “Questions and Answers About the Proposals” and “Summary of the Proxy Statement,” summarize information contained in this proxy statement/prospectus, but do not contain all of the information that is important to you. You should read carefully this entire proxy statement, including the attached annexes, for a more complete understanding of the matters to be considered at the Special Meeting. In addition, for definitions of terms commonly used throughout this proxy statement/prospectus, including in this Summary Term Sheet, see the section titled “Frequently Used Terms.”

● Data Knights Acquisition Corp., a Delaware corporation, which we refer to as “we,” “us,” “our,” “Company,” or “Data Knights,” is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.

● There are currently 14,960,275 shares of Data Knights Common Stock, par value $0.0001 per share, issued and outstanding, consisting of (i) 12,085,275 shares of Class A common stock (the “Class A Common Stock”), and (ii) 2,875,000 shares of Class B common stock (the “Class B Common Stock”), which were issued to our Sponsor prior to our IPO. There are currently no shares of Data Knights preferred stock issued and outstanding. In addition, we issued 11,500,000 public warrants to purchase Class A Common Stock (originally sold as part of the units issued in our IPO) as part of our IPO along with 585,275 Private Placement Units, each consisting of one share of Class A Common Stock and one Private Placement Warrant, issued to our Sponsor in a private placement on the IPO closing date. Each warrant entitles its holder to purchase one share of our Class A Common Stock at an exercise price of $11.50 per share, to be exercised only for a whole number of shares of our Class A Common Stock. The warrants will become exercisable 30 days after the completion of our initial business combination, and they expire five years after the completion of our initial business combination or earlier upon redemption or liquidation. Once the warrants become exercisable, the Company may redeem the outstanding warrants at a price of $0.01 per warrant, if the last sale price of the Company’s Common Stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third business day before the Company sends the notice of redemption to the warrant holders. The Private Placement Warrants, however, are non-redeemable so long as they are held by our Sponsor or its permitted transferees. For more information regarding the warrants, please see the section entitled “Description of the Securities”.

● Holders of Class A Common Stock and holders of Class B Common Stock are entitled to one vote for each share held on all matters to be voted on by stockholders and will vote together as a single class on all matters submitted to a vote of our stockholders except as otherwise required by law. The Class B Common Stock held by our Sponsor will automatically convert into shares of Class Common A Stock at the completion of our initial business combination. Assuming no additional shares of Class A Common Stock, or securities convertible into or exchangeable for, shares of Class A Common Stock, are issued by us in connection with or in relation to the consummation of our initial business combination, the 2,875,000 shares of Class B Common Stock will, pursuant to our Second Amended and Restated Certificate of Incorporation, automatically convert, on a one-for-one basis, into 2,875,000 shares of Class A Common Stock at the closing of our initial business combination.

● On April 25, 2022, we, the Merger Sub and our Sponsor entered into the Merger Agreement with OneMedNet and the Seller Representative, pursuant to which Merger Sub will merge with and into OneMedNet, with OneMedNet continuing as the surviving corporation and wholly-owned subsidiary of Data Knights, which will change its name to “OneMedNet Corporation” at the Closing. A copy of the Merger Agreement is attached to this proxy statement as Annex A.

● OneMedNet’s innovation solutions connect healthcare providers and patients, offering direct access to clinical images and associated contextual patient record. For more information about OneMedNet, please see the sections entitled “Information About OneMedNet,” “OneMedNet’s Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Management after the Business Combination.”

● Subject to the terms of the Merger Agreement, the aggregate purchase price for the Business Combination and related transactions is approximately $200,000,000. The consideration to be paid to the stockholders of OneMedNet will be shares of

Data Knights Class A Stock having a value equal to $200,000,000 minus (i) the amount, if any, by which the Target Net Working Capital Amount (as defined in the Merger Agreement) exceeds the Net Working Capital Amount (as defined in the Merger Agreement) (but not less than zero), minus (ii) the amount of Closing Net Indebtedness (as defined in the Merger Agreement) minus (iii) the amount of any Merger transaction expenses.

● Pursuant to the Merger Agreement, the Company has agreed to use its reasonable commercial efforts to obtain at least $30,000,000 of additional equity capital through the sale of at least 3,000,000 shares of its Class A Common Stock at a purchase price of $10.00 per share to private investors (the “PIPE Financing”). There can be no assurance that the Company will be able to arrange the PIPE Financing and doing so is not a condition to closing. See Risk Factors.

● Our management and Board considered various factors in determining whether to approve the Merger Agreement and the transactions contemplated thereby, including the Business Combination, the revenue and earnings growth potential of OneMedNet, the prospects for service providers to medical-related businesses and the strength of OneMedNet’s management team, which the Board believes positions OneMedNet for future growth and profitability. For more information about our Board’s decision-making process, see the section entitled “Proposal No. 1—The Business Combination Proposal — The Board’s Reasons for Approval of the Business Combination.”

● Pursuant to the Data Knights Charter, in connection with the Business Combination, holders of our Public Shares may elect to have their Class A Common Stock redeemed for cash at the applicable redemption price per share calculated in accordance with the Data Knights Charter. As of July 1, 2022 the redemption price would have been approximately $10.32 per share based on funds in the Trust Account of approximately $118,700,000. If a holder exercises its redemption rights, then such holder will be exchanging its shares of our Class A Common Stock for cash and will no longer own shares of the post-combination company and will not participate in the future growth of the post-combination company, if any. Such a holder will be entitled to receive cash for its Public Shares only if it properly demands redemption and delivers its shares (either physically or electronically) to our transfer agent at least two business days prior to the Special Meeting. Please see the section entitled “Special Meeting of Data Knights Stockholders — Redemption Rights.”

● In addition to voting on the proposal to adopt the Merger Agreement and approve the transactions contemplated thereunder, including the Business Combination, at the Special Meeting, Data Knight stockholders will be asked to vote on:

● a proposal to approve, for purposes of complying with applicable Nasdaq Listing Rules, the issuance of more than 20% of the Company’s issued and outstanding Common Stock in connection with the PIPE (the “Nasdaq Proposal” or “Proposal No. 2”);

● a proposal to adopt the Third Amended and Restated Certificate of Incorporation in the form attached hereto as Annex B (the “Charter Amendment Proposal” or “Proposal No. 3”);

● a proposal to elect directors to our Board to serve in a class of directors whose terms expire at the annual meeting of our stockholders to be held in 2023, 2024 and 2025 or until each such director’s successor has been duly elected and qualified, or until each such director’s earlier death, resignation, retirement, or removal (the “Election of Directors Proposal” or “Proposal No. 4”);

● a proposal to approve the Equity Incentive Plan, including the authorization of the initial share reserve under the Equity Incentive Plan (the “Incentive Plan Proposal” or “Proposal No. 5”); and

● a proposal to adjourn the Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Business

Combination Proposal, the Nasdaq Proposal, the Charter Amendment Proposal, the Election of Directors Proposal, or the Incentive Plan Proposal (the “Adjournment Proposal” or “Proposal No. 6”).

Please see the sections entitled “Proposal No. 1 — Business Combination Proposal,” “Proposal No. 2 — The Nasdaq Proposal,” “Proposal No. 3 — The Charter Proposal,” “Proposal No. 4 — Election of Directors Proposal,” “Proposal No. 5 — Incentive Plan Proposal,” and “Proposal No. 6 — The Adjournment Proposal.” Unless waived by the parties to the Merger Agreement, the closing of the Business Combination is conditioned on the approval of the Business Combination Proposal, the Nasdaq Proposal, the Charter Amendment Proposal, the Election of Directors Proposal, and the Incentive Plan Proposal at the Special Meeting. Each of the proposals at the Special Meeting, other than the Adjournment Proposal, is conditioned on the approval of the others. The Adjournment Proposal is not conditioned on the approval of any other proposal set forth in this proxy statement.

● Upon consummation of the Business Combination, we anticipate a Board of nine directors, of whom two individuals shall be designated by the Company, with the remaining seven individuals designated by OneMedNet. The nine directors shall be divided into three classes, with the first class consisting of four (4) directors with an initial term that expires in 2023, the second class consisting of two (2) directors with an initial term that expires in 2024, and the third class consisting of three (3) directors with an initial term that expires in 2025. Such directors shall serve until their respective successors are duly elected and qualified, or until their earlier resignation, removal, or death. Please see the sections entitled “Proposal No. 3 — Charter Amendment Proposal” and “Management After the Business Combination” for additional information.

● Unless waived by the parties to the Merger Agreement, and subject to applicable law, the closing of the Business Combination is subject to a number of conditions set forth in the Merger Agreement. For more information about the closing conditions to the Business Combination, please see the section entitled “Proposal No. 1 — The Business Combination Proposal — The Merger Agreement — Conditions to the Closing.”

● The Merger Agreement may be terminated at any time prior to the consummation of the Business Combination upon agreement of the parties thereto, or by certain parties in specified circumstances. For more information about the termination rights under the Merger Agreement, please see the section entitled “Proposal No. 1 — The Business Combination Proposal — The Merger Agreement — Termination.”

● The proposed Business Combination involves numerous risks. For more information about these risks, please see the section entitled “Risk Factors.”

● Upon consummation of the Business Combination, we will enter into an Executive Employment Agreements with certain officers of OneMedNet to be effective as of the closing of the Business Combination, pursuant to which such officers will serve as our officers and the officers of OneMedNet. For more information about the Executive Employment Agreements, please see the section entitled “Management after the Business Combination — Post-Combination Company Executive Compensation — Employment Agreements.”

● At the execution of the Merger Agreement, certain significant holders of OneMedNet shares as defined in the Merger Agreement (the “Significant Company Holders”) entered into Lock-Up Agreements with Data Knights, pursuant to which, among other things, and subject to certain exceptions, provide for the securities of Data Knights held by the Significant Company Holders to be locked-up for the earlier of (a) a period of six months from the date of the closing of the Business Combination, or (b) the date after the closing of the Business Combination on which we consummate a liquidation, merger, capital stock exchange, reorganization, or other similar transaction with an unaffiliated third party that results in all of our stockholders having the right to exchange their shares for cash, securities, or other property. We will be subject to certain restrictions on sale thereafter, in accordance with the terms set forth therein. We will also enter into the Registration Rights Agreement, pursuant to which, among other things, we will be obligated to file a registration statement to register the resale of certain securities of the Company, as well as provide OneMedNet with “piggy-back” registration rights, subject to certain requirements and customary conditions. Certain stockholders have also entered into Non-Competition Agreements, pursuant

to which the subject parties thereto agreed to certain non-competition, non-solicitation, and confidentiality restrictions in favor of Data Knights and its affiliates.

● In considering the recommendation of our Board to vote for the proposals presented at the Special Meeting, including the Business Combination Proposal, you should be aware that aside from their interests as stockholders, our Sponsor and certain members of our Board and officers may have interests in the Business Combination that are different from, or in addition to, the interests of our stockholders generally. Our Board was aware of and considered these interests, among other matters, in evaluating and negotiating the Business Combination and transaction agreements and in recommending to our stockholders that they vote in favor of the proposals presented at the Special Meeting, including the Business Combination Proposal. Stockholders should take these interests into account in deciding whether to approve the proposals presented at the Special Meeting, including the Business Combination Proposal.

​

​

FREQUENTLY USED TERMS

Unless otherwise stated or unless the context otherwise requires, the terms “we,” “us,” “our,” “Company,” and “Data Knights” refer to Data Knights Acquisition Corp. As used in this proxy statement/prospectus, unless otherwise noted or the context otherwise requires:

“Board” shall mean the board of directors of Data Knights.

“Business Combination” shall mean the Merger and the other transactions contemplated by the Merger Agreement whereby, among other things, Merger Sub will merge with and into OneMedNet, with OneMedNet surviving as a wholly-owned subsidiary of Data Knights, and Data Knights changing its name to OneMedNet.

“Business Combination Date” shall mean [•], 2022.

“Charter” shall mean Data Knights’ Second Amended and Restated Certificate of Incorporation.

“Common Stock” shall mean shares of Data Knights Class A Common Stock and Data Knights Class B Common Stock, collectively.

“Closing” shall mean the closing of the Business Combination.

“Closing Company Cash” shall mean, as of a reference time, the aggregate cash and cash equivalents of OneMedNet and its subsidiaries on hand or in bank accounts, including deposits in transit, minus the aggregate amount of outstanding and unpaid checks issued by or on behalf of the OneMedNet and its subsidiaries of such time.

“Closing Date” shall mean [•], 2022.

“Closing Net Indebtedness” shall mean the amount by which the aggregate amount of any outstanding indebtedness of OneMedNet exceeds the cash held by OneMedNet at Closing.

“Code” shall mean the Internal Revenue Code of 1986, as amended.

“Combined Entity” shall mean Data Knights after giving effect to the Business Combination and the change of its name to OneMedNet Corporation, and which will include its direct and indirect subsidiaries.

“Continental” shall mean Continental Stock Transfer & Trust Company, Data Knights’ transfer agent.

“Data Knights” shall mean Data Knights Acquisition Corp., a Delaware corporation.

“Data Knights Board” shall mean the board of directors of Data Knights.

“Data Knights Charter” shall mean Data Knights’ Second Amended and Restated Certificate of Incorporation.

“Data Knights Class A Common Stock” shall mean the shares of Class A common stock, par value $0.0001 per share, of Data Knights.

“Data Knights Class B Common Stock” shall mean the shares of Class B common stock, par value $0.0001 per share, of Data Knights.

“Data Knights Common Stock” shall mean shares of Data Knights Class A Common Stock and Data Knights Class B Common Stock, collectively.

“Data Knights IPO” shall mean Data Knights’ initial public offering.

“DGCL” shall mean the Delaware General Corporation Law, as amended.

“EF Hutton” shall mean EF Hutton, division of Benchmark Investments, Inc. (formerly, Kingswood Capital Markets), who is the representative of the underwriters in the Data Knights IPO.

“Effective Time” shall mean the time when the Business Combination is consummated, upon the filing of the Certificate of Merger for the merger of Merger Sub with and into Data Knights with the Delaware Secretary of State in accordance with the relevant provisions of the DGCL.

“Equity Incentive Plan” shall mean the 2022 Equity Incentive Plan substantially in the form of Exhibit F to the Merger Agreement.

“Escrow Agent” shall mean Truist Bank, a North Carolina banking corporation.

“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

“Extension Escrow Agreement” shall mean that certain Extension Escrow Agreement dated as of April 25, 2022, by and among Data Knights, OneMedNet, and Truist Bank.

“Extension Units” shall mean Units issued by Data Knights upon any conversion of any extension payments made by the Sponsor to the Trust Account.

“Founders” shall mean Data Knights, LLC, Barry Anderson, Firdauz Edmin Bin Mokhtar, Syed Musheer Ahmed, Dr. Julianne Huh and Annie Damit Undikai, and any successors in interest thereto with respect to any Founder Shares.

“Founder Shares” shall mean shares of Data Knights Class B Common Stock, par value $0.0001 per share, purchased by the Sponsor in a private placement prior to the Data Knights IPO.

“HSR Act” shall mean the Hart-Scott-Rodino Antitrust Act.

“Illustrative Maximum Redemptions” shall mean the amount which represents the maximum number of redemptions that may occur of Data Knights Public Shares without a shortfall of cash while still satisfying the conditions to the Business Combination.

“Insiders” shall mean holders of Founder Shares prior to Data Knights IPO.

“IPO” shall mean Data Knights’ initial public offering of units, consummated on May 11, 2021.

“Letter of Transmittal” shall mean that certain letter substantially in the form of Exhibit E to the Merger Agreement.

“Lock-Up Agreements” shall mean those certain Lock-Up Agreements dated as of April 25, 2022, entered into by Data Knights with certain significant OneMedNet stockholders, substantially in the form of Exhibit C to the Merger Agreement.

“Material Adverse Effect” shall have the meaning assigned such term in the Merger Agreement.

“Maximum Redemption Scenario” shall mean an assumption that 100% of the holders of Data Knights’ Public shares will exercise their right to have their Public Shares redeemed for cash, which is the maximum amount that may be redeemed without a cash shortfall, while still satisfying the conditions to the Business Combination.

“Merger” shall mean the merger of Merger Sub with and into OneMedNet, with OneMedNet continuing as the surviving corporation and wholly-owned subsidiary of Data Knights, as contemplated by the Merger Agreement.

“Merger Agreement” shall mean that certain Agreement and Plan of Merger dated as of April 25, 2022, as it may be amended or supplemented from time to time, by and among the Company, Data Knights Merger Sub, Inc., Data Knights, LLC, Paul Casey, solely in his capacity as seller representative, and OneMedNet Corporation.

“Merger Consideration” (a) Two Hundred Million U.S. Dollars ($200,000,000) minus (b) the amount, if any, by which the Target Net Working Capital Amount (as defined in the Merger Agreement) exceeds the Net Working Capital Amount (but not less than zero) (as defined in the Merger Agreement), minus (c) the amount of Closing Net Indebtedness (as defined in the Merger Agreement) minus (d) the amount of any Merger transaction expenses.

“Merger Sub” shall mean Data Knights Merger Sub, Inc., a Delaware corporation, and a wholly-owned subsidiary of Data Knights.

“Nasdaq” shall mean the Nasdaq Capital Market.

“Nelson Mullins” shall mean Nelson Mullins Riley & Scarborough LLP, counsel to Data Knights.

“Net Working Capital Amount” shall mean, as of the Reference Time, (i) all current assets of OneMedNet and its subsidiaries (excluding, without duplication, Closing Company Cash), on a consolidated basis, minus (ii) all current liabilities of the OneMedNet and its subsidiaries (excluding, without duplication, Indebtedness and unpaid Transaction Expenses), on a consolidated basis and as determined in accordance with the Accounting Principles; provided, that, for purposes of this definition, whether or not the following is consistent with the Accounting Principles, “current assets” will exclude any receivable from a OneMedNet Stockholder.

“New OneMedNet” shall mean the Combined Entity.

“Non-Competition Agreements” shall mean those certain Non-Competition and Non-Solicitation Agreements dated as of April 25, 2022, by and between Data Knights and certain significant OneMedNet stockholders, substantially in the form of Exhibit D to the Merger Agreement.

“OneMedNet” shall mean OneMedNet Corporation, a Delaware corporation.

“PIPE Investors” shall mean those investors that purchased Data Knights Common Stock pursuant to subscription agreements.

“PIPE Shares” shall mean Data Knights Common Stock to be purchased by PIPE Investors pursuant to subscription agreements.

“Placement Shares” shall mean the shares of Data Knights Class A common stock included within the Placement Units being purchased by our sponsor in the private placement.

“Placement Units” or “Private Placement Units” shall mean the units purchased in a private placement in connection with the IPO, each unit consisting of one share of Data Knights Common Stock and one warrant to purchase Data Knights Common Stock.

“Private Placement Warrants” shall mean the warrants to purchase Data Knights Common Stock underlying the private units.

“Proposals” shall mean the Business Combination Proposal, the Charter Amendments Proposal, the Nasdaq Proposal, the Director Election Proposal, the Incentive Plan Proposal, and the Adjournment Proposal.

“Public Shares” shall mean the Data Knights Class A Common Stock underlying the public units issued and sold in the Data Knights IPO.

“Public Units” shall mean the units issued and sold in the Data Knights IPO.

“Public Warrants” shall mean the warrants underlying the public units issued in the Data Knights IPO.

“Purchaser Representative” shall mean Data Knights, LLC.

“Record Date” shall mean [•], 2022.

“redeemable” shall mean, in respect of the public warrants, the ability of Data Knights to redeem such public warrants after the closing of the proposed Business Combination, provided that certain other conditions as set forth in the warrant agreement between Continental and Data Knights are met.

“redemption” shall mean the right of Data Knights stockholders to have their Public Shares redeemed in accordance with the procedures set forth in this proxy statement/prospectus.

“Registration Rights Agreement” shall mean the Registration Rights Agreement by and among Data Knights, the Founders, and certain OneMedNet stockholders in substantially the form of Exhibit G to the Merger Agreement.

“SEC” shall mean the United States Securities and Exchange Commission.

“Second Amended and Restated Certificate of Incorporation” shall mean Data Knights’ Charter which is its Second Amended and Restated Certificate of Incorporation, dated April 6, 2021, as amended to date.

“Securities Act” shall mean the Securities Act of 1933, as amended.

“Seller Representative” shall mean Paul Casey, Chief Executive Officer of OneMedNet.

“Special Meeting” shall mean the special meeting of the stockholders of Data Knights, to be held on [•], 2022 at [•], which will be a virtual meeting conducted via live webcast.

“Sponsor” shall mean Data Knights, LLC, a Delaware limited liability company.

“Sponsor Support Agreement” shall mean that certain Sponsor Support Agreement dated as of April 25, 2022, by and among Data Knights, Sponsor, and OneMedNet, whereby, among other things, Sponsor has agreed to vote its shares of Data Knights Common Stock in favor of the adoption and approval of the Merger Agreement and the transactions contemplated thereby, substantially in the form of Exhibit B to the Merger Agreement.

“Trust Account” shall mean the trust account of Data Knights, which holds the net proceeds of the Data Knights IPO, together with interest earned thereon, less amounts released to pay franchise and income tax obligations.

“Trust Agent” shall mean Continental Stock Transfer & Trust Company, Data Knights’ transfer agent.

“Voting Agreement” shall mean that certain Voting agreement dated as of April 25, 2022, by and among Data Knights, OneMedNet, and certain OneMedNet stockholders, substantially in the form of Exhibit A to the Merger Agreement.

“Warrants” shall mean Data Knights redeemable warrants, which includes the Public Warrants as well as the Private Placement Warrants and any warrants issued upon conversion of working capital loans to the extent they are no longer held by the initial holders or their permitted transferees.

“Working Capital Units” shall mean Units issued by Data Knights upon any conversion of any working capital loans made by the Sponsor to Data Knights.

​

​

QUESTIONS AND ANSWERS ABOUT THE PROPOSALS

The following questions and answers briefly address some commonly asked questions about the Proposals to be presented at the Special Meeting of Data Knights stockholders. The following questions and answers do not include all the information that is important to stockholders of Data Knights. We urge the stockholders of Data Knights to read this entire proxy statement carefully, including the annexes and other documents referred to herein.

Q.Why am I receiving this proxy statement/prospectus?

Your vote is important. You are encouraged to submit your proxy as soon as possible after carefully reviewing this proxy statement/prospectus and its annexes.

Below are proposals on which Data Knights stockholders are being asked to vote.

Q.Are the Proposals conditioned on one another?

Q.What will happen in the Business Combination?

The number of shares and percentage interests set forth in the above table under either redemption scenario do not take into account (i) potential future exercises of up to 11,500,000 Public Warrants and up to 585,275 Private Placement Warrants, which will remain outstanding immediately following the Business Combination and may be exercised thereafter at an exercise price of $11.50 (commencing 30 days after the Closing of the Business Combination), (ii) 806,453 shares issuable upon the exercise of outstanding options to purchase shares of OneMedNet common stock, (iii) up to 360,000 shares issuable pursuant to the Equity Incentive Plan, or (iv) warrants to purchase up to 150,000 units if the Sponsor makes a working capital loan prior to the closing of the Business Combination in an amount up to $1,500,000 (no such loans have been made to date) and elects to convert such working capital loan into units. The exercise, issuance or vesting of any of these shares could have a dilutive effect on those of our stockholders who do not elect to redeem their shares. If all such shares were issued immediately after the Business Combination, based on the number of issued and outstanding shares of Data Knights Common Stock, non-redeeming Public Stockholders, as a group, would own:

● if there are no redemptions of Public Shares, 32.9% of the Data Knights Common Stock outstanding assuming all such shares were issued immediately after the Business Combination; or

● if there are maximum redemptions of 100% of the outstanding Public Shares, none of the Data Knights Common Stock outstanding assuming all such shares were issued immediately after the Business Combination.

If the actual facts are different than the assumptions set forth above, the share numbers set forth above will be different. For more information, please see the section entitled “Unaudited Pro Forma Condensed Combined Financial Information.”

Q.How much consideration will OneMedNet Stockholders receive in connection with the Business Combination?

Q.Why is Data Knights Proposing the Business Combination?

OneMedNet is an expert and leader in clinical imaging innovation solutions that connects healthcare providers and patients and satisfies a crucial need with the life sciences. It offers direct access to clinical images and associated contextual patient record. OneMedNet proved the commercial and regulatory viability of imaging Regulatory Grade Real-World Data (“iRWD^TM”), a promising emerging market, that exactly matches OneMedNet’s life science partners’ case selection protocol. With a growing federated network of 90+ healthcare providers, OneMedNet has the immediate ability to quickly search and extensively curate multi-layer data from a Federated group of healthcare facilities. OneMedNet is an expert in secure data interoperability, providing fast access to curated medical images that has proved the commercial and regulatory viability of imaging RWD and covers the complete value chain in imaging RWD, validated by an increasing federated network of providers.

Based on its due diligence investigation of OneMedNet and the industry in which it operates, including the financial and other information provided by OneMedNet in the course of their negotiations in connection with the Merger Agreement, Data Knights believes OneMedNet is well-positioned in its industry for growth, that its business provides a valuable service, and that it possesses a strong management team, of which the senior management intends to remain in the capacity of officers and/or

directors. As a result, Data Knights believes that the Business Combination will provide Data Knights stockholders with an opportunity to participate in the ownership of a company with significant growth potential.

Q.What conditions must be satisfied to complete the Business Combination?

● the approval by the stockholders of each of OneMedNet and Data Knights;

● approvals of any required governmental authorities and the expiration or termination of any anti-trust waiting periods;

● receipt of specified third-party consents;

● no law or order preventing the transactions;

● no material uncured breach by the other party;

● after giving effect to the redemption, Data Knights shall have at least $5,000,001 of net tangible assets as required by its charter;

● the members of the post-Closing Data Knights board shall have been elected or appointed as of the Closing;

● the Registration Statement shall have been declared effective by the SEC and shall remain effective as of the Closing, and no stop order or similar order shall be in effect with respect to the Registration Statement; and

● the shares of Data Knights Common Stock issued as Merger Consideration shall have been approved for listing on Nasdaq, subject to official notice of issuance.

In addition, unless waived by OneMedNet, the obligations of OneMedNet to consummate the Merger are subject to the satisfaction of the following Closing conditions, in addition to customary certificates and other closing deliveries: (a) the representations and warranties of Data Knights being true and correct as of the date of the Merger Agreement and as of the Closing (subject to Material Adverse Effect); (b) Data Knights having performed in all material respects the respective obligations and complied in all material respects with their respective covenants and agreements under the Merger Agreement required to be performed or complied with on or prior the date of the Closing; (c) absence of any Material Adverse Effect with respect to Data Knights since the date of the Merger Agreement which is continuing and uncured; and (d) the Registration Rights Agreement being in full force and effect as of the Closing.

Unless waived by Data Knights, the obligations of Data Knights and Merger Sub to consummate the Merger are subject to the satisfaction of the following Closing conditions, in addition to customary certificates and other closing deliveries: (a) the representations and warranties of OneMedNet being true and correct as of the date of the Merger Agreement and as of the Closing (subject to Material Adverse Effect); (b) OneMedNet having performed in all material respects the respective obligations and complied in all material respects with its covenants and agreements under the Merger Agreement required to be performed or complied with on or prior the date of the Closing; and (c) absence of any Material Adverse Effect with respect to OneMedNet as a whole since the date of the Merger Agreement which is continuing and uncured; and (d) each Executive Employment Agreement, Lock-Up Agreement and Non-Competition Agreement being in full force and effect as of the Closing.

For a summary of the conditions that must be satisfied or waived prior to the Closing of the Business Combination, see the section titled “The Business Combination Proposal — The Merger Agreement.”

Q.What vote is required to approve the Proposals presented at the Special Meeting?

The approval of the Nasdaq Proposal and the Incentive Plan Proposal each require the affirmative vote of the holders of a majority of the shares of Data Knights Common Stock cast by the stockholders represented in person or by proxy and entitled to vote thereon at the Special Meeting. A Data Knights stockholder’s failure to vote by proxy or to vote in person at the Special Meeting will not be counted towards the number of shares of Data Knights Common Stock required to validly establish a quorum, and if a valid quorum is otherwise established, it will have no effect on the outcome of the vote on the Nasdaq Proposal and the Incentive Plan Proposal.

If the Business Combination is not approved, the Nasdaq Proposal, the Charter Amendment Proposal, the Election of Directors Proposal, and the Incentive Plan Proposal will not be presented to Data Knights’ stockholders for a vote. The approval of the Business Combination, the Nasdaq Proposal, the Charter Amendment Proposal, the Election of Directors Proposal, and the Incentive Plan Proposal are preconditions to the consummation of the Business Combination.

Q.How will Data Knights’ Sponsor, directors, and officers vote?

● unless Data Knights consummates an initial business combination, Data Knights’ officers, directors, and the Sponsor will not receive reimbursement for any out-of-pocket expenses incurred by them to the extent that such expenses exceed the amount of available proceeds not deposited in the Trust Account;

● as a condition to the Data Knights IPO, all of the Founder Shares are subject to a lock-up and would be released only if specified conditions were met. In particular, subject to certain limited exceptions, all Founder Shares would be subject to a lock up until the earlier of (A) six months after the completion of Data Knights’ Business Combination and (B) subsequent to the Business Combination, (x) if the closing price of the Class A Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any

30-trading day period commencing at least 150 days after the Business Combination or (y) the date on which Data Knights completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of the Company’s stockholders having the right to exchange their shares of Class A Common Stock for cash, securities or other property;

● the Placement Units, purchased by the Sponsor will be worthless if a business combination is not consummated;

● the Sponsor has agreed that the Placement Units and the underlying securities, will not be sold or transferred by it until after Data Knights has completed a business combination, subject to limited exceptions;

● the fact that Sponsor paid an aggregate of $25,000 for its Founder Shares and such securities will have a significantly higher value at the time of the Business Combination;

● the fact that Sponsor has agreed not to redeem any of the Founder Shares in connection with a stockholder vote to approve a proposed initial business combination;

● if Data Knights does not complete an initial business combination by November 11, 2022, the proceeds from the sale of the Placement Units will be included in the liquidating distribution to Data Knights’ Public Stockholders and the Placement Units will expire worthless; and

● if the Trust Account is liquidated, including in the event Data Knights is unable to complete an initial business combination within the required time period, the Sponsor has agreed to indemnify Data Knights to ensure that the proceeds in the Trust Account are not reduced below $10.20 per Public Share by the claims of prospective target businesses with which Data Knights has entered into an acquisition agreement or claims of any third party for services rendered or products sold to Data Knights, but only if such a vendor or target business has not executed a waiver of any and all rights to seek access to the Trust Account.

These interests may influence Data Knights’ directors in making their recommendation that you vote in favor of the approval of the Business Combination. The estimated aggregate amount invested by Sponsor and certain of Data Knights' directors and executive officers in their interests in Data Knights is $5,877,750.

electronically) to Data Knights’ Transfer Agent prior to the Special Meeting. See the section titled “Special Meeting of Data Knights Stockholders — Redemption Rights” for the procedures to be followed if you wish to redeem your shares for cash.

To exercise your redemption rights, you must demand that the Company redeem your Public Shares. In connection with tendering your shares for redemption, you must elect either to physically tender your share certificates to Continental, at Continental Stock Transfer & Trust Company, One State Street Plaza, 30^th Floor, New York, New York 10004-1561, Attn: Mark Zimkind, at least two (2) business days prior to the Special Meeting or deliver your shares to Continental electronically using The Depository Trust Company’s DWAC (Deposit/Withdrawal At Custodian) System, which election would likely be determined based on the manner in which you hold your shares.

Certificates that have not been tendered in accordance with these procedures at least two (2) business days prior to the Special Meeting will not be redeemed for cash. In the event that a public stockholder tenders its shares and decides that it does not want to redeem its Public Shares, such stockholder may withdraw the tender. If you delivered your Public Shares for redemption to Continental and decide prior to the Special Meeting not to redeem your Public Shares, you may request that Continental return the shares (physically or electronically). You may make such request by contacting Continental at the address listed below:

Continental Stock Transfer & Trust Company

One State Street Plaza, 30^th Floor

New York, New York 10004-1561

Attn: Mark Zimkind

E-mail: mzimkind@continentalstock.com

Notwithstanding the foregoing, a holder of the Public Shares, together with any affiliate of his or any other person with whom he is acting in concert or as a “group” (as defined in Section 13d-3 of the Exchange Act) will be restricted from seeking redemption rights with respect to an aggregate of 15% or more of the shares of Data Knights Common Stock included in the Public Units sold in the Data Knights IPO, which we refer to as the “15% threshold.” Accordingly, all Public Shares in excess of the 15% threshold beneficially owned by a Public Stockholder or group will not be redeemed for cash.

Stockholders seeking to exercise their redemption rights and opting to deliver physical certificates should allot sufficient time to obtain physical certificates from the Transfer Agent and time to effect delivery. It is Data Knights’ understanding that stockholders should generally allot at least two weeks to obtain physical certificates from the Transfer Agent. However, Data Knights does not have any control over this process, and it may take longer than two weeks. Stockholders who hold their shares in street name will have to coordinate with their bank, broker or other nominee to have the shares certificated or delivered electronically.

Any demand for redemption, once made, may be withdrawn at any time until the deadline for exercising redemption requests and thereafter, with Data Knights’ consent, until the vote is taken with respect to the Business Combination. If you delivered your shares for redemption to Data Knights’ Transfer Agent and decide within the required timeframe not to exercise your redemption rights, you may request that Data Knights’ Transfer Agent return the shares (physically or electronically). You may make such request by contacting Data Knights’ Transfer Agent at the phone number or address listed under the question “Who can help answer my questions?” below.

If you hold Units registered in your own name, you must deliver the certificate for such Units to Continental Stock Transfer & Trust Company, Data Knights’ Transfer Agent, with written instructions to separate such Units into Public Shares and Public Warrants. This must be completed far enough in advance to permit the mailing of the Public Share certificates back to you so that you may then exercise your redemption rights upon the separation of the Public Shares from the Units. See “How do I exercise my redemption rights?” above. The address of Continental Stock Transfer & Trust Company is listed under the question “Who can help answer my questions?” below.

If a broker, dealer, commercial bank, trust company, or other nominee holds your units, you must instruct such nominee to separate your Units. Your nominee must send written instructions by facsimile to Continental Stock Transfer & Trust Company, Data Knights’ Transfer Agent. Such written instructions must include the number of Units to be split and the nominee holding such Units. Your nominee must also initiate electronically, using DTC’s deposit withdrawal at custodian (DWAC) system, a withdrawal of the relevant units and a deposit of an equal number of Public Shares, and Public Warrants. This must be completed far enough in advance to permit your nominee to exercise your redemption rights upon the separation of the Public Shares from the Units. While this is typically done electronically the same business day, you should allow at least one full business day to accomplish the separation. If you fail to cause your Public Shares to be separated in a timely manner, you will likely not be able to exercise your redemption rights.

● a portion of the Merger Consideration pursuant to the Merger Agreement;

● Data Knights stockholders who properly exercise their redemption rights;

● $4,025,000 payable to EF Hutton, a division of Benchmark Investments, Inc. for deferred underwriting commissions from the IPO;

● certain other fees, costs, and expenses (including regulatory fees, legal fees, accounting fees, printer fees, and other professional fees) that were incurred by Data Knights or OneMedNet in connection with the transactions contemplated by the Business Combination and pursuant to the terms of the Merger Agreement;

● any loans owed by Data Knights to its Sponsor for any Data Knights transaction expenses or other administrative expenses incurred by Data Knights; and

● for general corporate purposes including, but not limited to, working capital for operations.

If, as a result of the termination of the Merger Agreement or otherwise, Data Knights is unable to complete the Business Combination or another initial business combination transaction by November 11, 2022, Data Knights’ Charter provides that it will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible, subject to lawfully available funds therefor, redeem 100% of the Public Shares in consideration of a per-share price, payable in cash, equal to the quotient obtained by dividing (A) the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to it to pay franchise and income taxes payable, by (B) the total number of then outstanding Public Shares, which redemption will completely extinguish rights of the Public Stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemptions, subject to the approval of Data Knights’ remaining stockholders and Data Knights’ Board in accordance with applicable law, dissolve and liquidate, subject (in the case of (ii) and (iii) above) to its obligations under the DGCL to provide for claims of creditors and other requirements of applicable law.

Data Knights expects that the amount of any distribution its Public Stockholders will be entitled to receive upon its dissolution will be approximately the same as the amount they would have received if they had redeemed their shares in connection with the Business Combination, subject in each case to Data Knights’ obligations under the DGCL to provide for claims of creditors and other requirements of applicable law. Holders of Founder Shares have waived any right to any liquidation distribution with respect to those shares.

In the event of liquidation, there will be no distribution with respect to Data Knights’ outstanding Warrants Accordingly, the Warrants will expire worthless.

of the Business Combination, see the section titled “The Business Combination Proposal — The Merger Agreement — Conditions to the Closing.”

Q.What will happen if I abstain from voting or fail to vote at the Special Meeting?

Q.What will happen if I sign and return my proxy card without indicating how I wish to vote?

You also may revoke your proxy by sending a notice of revocation to Data Knights’ secretary, which must be received by Data Knights’ secretary prior to the Special Meeting.

Data Knights Acquisition Corp.
Unit G6, Frome Business Park, Manor Road
Frome, United Kingdom, BA11 4FN
Attn: Barry Anderson
Telephone No.: 011-44 203 833 4000
E-mail: barry@dataknightsacuk.com

​

You may also contact our proxy solicitor at:

​

Laurel Hill Advisory Group, LLC

2 Robbins Lane, Suite 201

Jericho, NY 11753

(855) 414-2266

Email: dataknights@laurelhill.com

To obtain timely delivery, Data Knights stockholders must request the materials no later than five (5) business days prior to the Special Meeting.

You may also obtain additional information about Data Knights from documents filed with the SEC by following the instructions in the section titled “Where You Can Find More Information.”

If you intend to seek redemption of your Public Shares, you will need to send a letter demanding redemption and deliver your stock (either physically or electronically) to Data Knights’ Transfer Agent prior to the Special Meeting in accordance with the procedures detailed under the question “How do I exercise my redemption rights?” If you have questions regarding the certification of your position or delivery of your stock, please contact:

Continental Stock Transfer & Trust Company

One State Street Plaza, 30^th Floor

New York, New York 10004-1561

Attn: Mark Zimkind

E-mail: mzimkind@continentalstock.com

​

​

​